公开(公告)号：KR101175460B1

公开(公告)日：2012-08-20

申请号：KR1020100068981

申请日：2010-07-16

Applicant: 성균관대학교산학협력단

Inventor： 이창우 ,  이자넷 ,  백선화 ,  이교원 ,  최규실

IPC: C12N5/074 ,  C12N5/079 ,  C12N15/54 ,  A61P25/00

Abstract: 본발명은사이클린의존성인산화효소(cyclin-dependent kinases, CDKs)의활성또는발현의조절에의해성체줄기세포로부터신경세포의교차분화및 신경세포로부터유도된만능줄기세포(induced pluriotent stem cell)로의역분화를유도하는방법에관한발명으로, 기존의신경세포분화유도에사용된첨가물을배제할수 있고, 분화의효율성도높일수 있다는장점이있어퇴행성뇌질환을포함한다양한신경계질환치료기법에응용될수 있을것이다.

公开(公告)号：KR1020130124270A

公开(公告)日：2013-11-13

申请号：KR1020130128011

申请日：2013-10-25

Applicant: 성균관대학교산학협력단

Inventor： 최규실 ,  서영주 ,  임현철 ,  김영선

IPC: A61K49/04 ,  A61K47/48 ,  A61K9/16

CPC classification number: A61K49/1824 ,  A61K49/14

Abstract: The present invention relates to an image material and a method for manufacturing the same and, more particularly, to an atherosclerotic plaque-specific MR image contrast agent and a method for manufacturing the same. The contrast agent of the present invention is an active contrast agent which is able to diagnose early atherosclerotic plaque and effectively realizes the atherosclerotic plaque-specific MR image by controlling the size of the phospholipid nanoparticles and extending the residence time of the phospholipid nanoparticles in the blood vessels. Also, the contrast agent is able to acquire an MR image using an amount less than the existing passive contrast agent and is able to easily diagnose diseases accompanying the atherosclerosis.

Abstract translation: 图像材料及其制造方法技术领域本发明涉及图像材料及其制造方法，更具体地，涉及动脉粥样硬化斑块特异性MR图像造影剂及其制造方法。 本发明的造影剂是能够诊断早期动脉粥样硬化斑块并有效实现动脉粥样硬化斑块特异性MR图像的活性造影剂，其通过控制磷脂纳米颗粒的尺寸并延长磷脂纳米颗粒在血液中的停留时间 船只。 此外，造影剂能够使用小于现有被动造影剂的量获得MR图像，并且能够容易地诊断伴随动脉粥样硬化的疾病。

公开(公告)号：KR1020120084466A

公开(公告)日：2012-07-30

申请号：KR1020110005843

申请日：2011-01-20

Applicant: 성균관대학교산학협력단

Inventor： 최규실 ,  서영주 ,  임현철 ,  김영선

IPC: A61K49/18 ,  A61K49/08 ,  A61K49/04 ,  A61P9/10

CPC classification number: A61K49/1809 ,  A61K47/544 ,  A61K49/0004 ,  Y10S514/824

Abstract: PURPOSE: A method for manufacturing an atherosclerotic plaque-specific MR contrast media is provided to enable early diagnosis of atherosclerotic plaque and to control the size of phospholipid nanoparticles. CONSTITUTION: An image material contains atherosclerotic plaque-specific target and MR contrast media conjugated to phospholipid nanoparticles(PLN). The average size of the nanoparticles is fai=5-100 nm. The contrast medium is gadolinium complex or iron oxide nanoparticles. The specific target contains pIL-4 peptide(LQRLFRAFRCLK)and cRGD(RGDfK).

Abstract translation: 目的：提供一种用于制造动脉粥样硬化斑块特异性MR造影剂的方法，以便早期诊断动脉粥样硬化斑块并控制磷脂纳米颗粒的大小。 构成：图像材料含有与磷脂纳米粒子（PLN）缀合的动脉粥样硬化斑块特异性靶标和MR造影剂。 纳米颗粒的平均尺寸为fai = 5-100nm。 造影剂是钆络合物或氧化铁纳米颗粒。 具体目标包含pIL-4肽（LQRLFRAFRCLK）和cRGD（RGDfK）。

公开(公告)号：KR1020120008239A

公开(公告)日：2012-01-30

申请号：KR1020100068981

申请日：2010-07-16

Applicant: 성균관대학교산학협력단

Inventor： 이창우 ,  이자넷 ,  백선화 ,  이교원 ,  최규실

IPC: C12N5/074 ,  C12N5/079 ,  C12N15/54 ,  A61P25/00

Abstract: PURPOSE: A method for differentiation and dedifferentiation between adult stem cells and neural cells is provided to enhance differentiation efficiency and to be applied in various therapeutic methods for treating nervous diseases. CONSTITUTION: A method for inducing differentiation between adult stem cells and neural cells comprises a step of controlling an inhibitor of expression or activation of CDKs(cyclin-dependent kinase). The adult stem cells are differentiated into neural cells by treating the inhibitor. The neural cells are dedifferentiated from neural cells into adult stem cells by removing the inhibitor. The inhibitor includes a compound, siRNA, shRNA, antisense olibonucleotide, or antibody. The shRNA for CDK1, CDK2, and CDK4 contains a base sequence of sequence numbers 13 or 14, 15 or 16, and 17 or 18, respectively.

Abstract translation: 目的：提供成体干细胞和神经细胞分化和去分化的方法，以提高分化效率，并应用于治疗神经疾病的各种治疗方法。 构成：诱导成体干细胞与神经细胞分化的方法包括控制CDK（细胞周期蛋白依赖性激酶）的表达或活化抑制剂的步骤。 通过治疗抑制剂将成体干细胞分化成神经细胞。 通过去除抑制剂，将神经细胞从神经细胞去分化成成体干细胞。 抑制剂包括化合物，siRNA，shRNA，反义寡核苷酸或抗体。 CDK1，CDK2和CDK4的shRNA含有序列号分别为13或14,15或16和17或18的碱基序列。